RAFA

A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
70 patients (estimated)
Sponsors
Children's Hospital Medical Center, Cincinnati
Collaborators
Memorial Sloan Kettering Cancer Center, Fred Hutchinson / University of Washington Cancer Consortium
Tags
Allogeneic Stem Cell Transplant, Chemotherapy
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1617
NCT Identifier
NCT02143830

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.